Acer Therapeutics | Sustainability Performance
Develops therapies for rare and serious diseases.
2014
United States
11 - 50 employees
Pharmaceuticals
$1M - 10M in revenue
N/A in profitability
Sustainability Ranking & Industry Benchmark
#7146
Overall#1544
in United States#166
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Revenue
R&D intensity
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$1.0MFY2021 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
-%FY2022
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
541.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 20.6%
0.2
2028Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
33%
Independent Directors
4 out of 12 incl. management
Overall score
60
Environment
61
Social
66
Governance
54
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
Reporting
Not reporting on Sustainability
Available